Han-Gil Jeong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Han-Gil Jeong has a total of 268 co-authors. Here are the top co-authors by number of shared publications:
Moon-Ku Han
Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
15 shared publicationsYong Soo Kim
Division of Intensive Care Medicine, Department of Neurosurgery and Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicne, Seongnam, Republic of Korea
9 shared publications- Beom Joon Kim
Ulsan University Hospital, University of Ulsan College of Medicine
7 shared publications - Dong-Wan Kang
Division of Neurocritical Care, Department of Neurosurgery and Neurology, Seoul National University Bundang Hospital, Seongnam, South Korea
7 shared publications Dong-Wan Kang
Division of Intensive Care Medicine, Department of Neurosurgery and Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicne, Seongnam, Republic of Korea
6 shared publications- Hee-Joon Bae
Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
6 shared publications
Latest Publications
- 24 August 2026
- Published by Springer Nature in Translational Stroke Research
- Vol. 17 (5) , 101
Beyond Acute Kidney Injury : Direct Pathways Implicate Inflammatory Mechanisms in Serum NGAL’s Mortality Effect in Acute Brain Injury
Neutrophil gelatinase-associated lipocalin (NGAL) is associated with mortality in critically ill patients, conventionally attributed to its role in acute kidney injury (AKI) detection. However, NGAL is a neutrophil granule protein released during innate immune activation—a process central to acute brain injury (ABI) pathophysiology. Whether the association between NGAL and mortality in neurocritical care operates through AKI-mediated or alternative pathways has not been evaluated. In this prospective cohort of 274 adults with ABI (98 intracerebral hemorrhage, 60 ischemic stroke, 46 subarachnoid hemorrhage, 70 traumatic brain injury) admitted to a neurocritical care unit, serum NGAL was measured within 24 h of admission. Causal mediation analysis with time-varying AKI status decomposed NGAL’s mortality effect into direct and AKI-mediated components. High NGAL (≥ 150 ng/mL) was independently associated with in-hospital mortality (adjusted hazard ratio [aHR] 2.94, 95% confidence interval [CI] 1.57–5.51; absolute risk difference 15.0% at 28 days), ICU mortality, 6-month mortality, and worse functional outcomes. Pathway decomposition revealed a significant direct effect not mediated through AKI (aHR 2.15, 95% CI 1.04–4.62, P=.04), whereas the AKI-mediated component was not significant (P=.33). Effects were consistent across injury types. Admission NGAL correlated with subsequent 72-hour systemic inflammatory burden (Spearman ρ = 0.38, P<.001), and within-subject NGAL and interleukin-6 showed concordant temporal trajectories (repeated-measures r = .29, P<.001). These findings indicate that the NGAL–mortality association in ABI includes a significant direct effect not mediated through AKI, implying that NGAL elevation reflects systemic innate immune activation rather than impending renal dysfunction.
- 24 August 2026
- Published by Springer Nature in Translational Stroke Research
- Vol. 17 (5) , 101
Beyond Acute Kidney Injury : Direct Pathways Implicate Inflammatory Mechanisms in Serum NGAL’s Mortality Effect in Acute Brain Injury
Neutrophil gelatinase-associated lipocalin (NGAL) is associated with mortality in critically ill patients, conventionally attributed to its role in acute kidney injury (AKI) detection. However, NGAL is a neutrophil granule protein released during innate immune activation—a process central to acute brain injury (ABI) pathophysiology. Whether the association between NGAL and mortality in neurocritical care operates through AKI-mediated or alternative pathways has not been evaluated. In this prospective cohort of 274 adults with ABI (98 intracerebral hemorrhage, 60 ischemic stroke, 46 subarachnoid hemorrhage, 70 traumatic brain injury) admitted to a neurocritical care unit, serum NGAL was measured within 24 h of admission. Causal mediation analysis with time-varying AKI status decomposed NGAL’s mortality effect into direct and AKI-mediated components. High NGAL (≥ 150 ng/mL) was independently associated with in-hospital mortality (adjusted hazard ratio [aHR] 2.94, 95% confidence interval [CI] 1.57–5.51; absolute risk difference 15.0% at 28 days), ICU mortality, 6-month mortality, and worse functional outcomes. Pathway decomposition revealed a significant direct effect not mediated through AKI (aHR 2.15, 95% CI 1.04–4.62, P=.04), whereas the AKI-mediated component was not significant (P=.33). Effects were consistent across injury types. Admission NGAL correlated with subsequent 72-hour systemic inflammatory burden (Spearman ρ = 0.38, P<.001), and within-subject NGAL and interleukin-6 showed concordant temporal trajectories (repeated-measures r = .29, P<.001). These findings indicate that the NGAL–mortality association in ABI includes a significant direct effect not mediated through AKI, implying that NGAL elevation reflects systemic innate immune activation rather than impending renal dysfunction.
- Open Access
- 28 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Hospital-level sepsis bundle compliance and its association with hospital performance in sepsis and septic shock in a nationwide cohort study
- 28 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessHospital-level sepsis bundle compliance and its association with hospital performance in sepsis and septic shock in a nationwide cohort study
- Open Access
- 12 June 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1741572
Ultra-early neurological pupil index trajectories and clinical outcomes in acute brain injury
Background and purpose: To investigate the association between ultra-early quantitative pupillometry indices measured within the first 24 h of emergency department (ED) arrival and clinical outcomes in patients with acute brain injury. Methods: This retrospective analysis of a prospectively collected database assessed patients admitted to the ICU of a tertiary hospital for acute brain injury (aneurysmal subarachnoid hemorrhage, traumatic brain injury, intracerebral hemorrhage, and ischemic stroke) between September 2022 and July 2024. Automated pupillometry was performed at 0, 1, 3, 6, and 24 h after ED arrival. Neurological pupil index (NPi) trajectories were categorized into four clusters ( Consistently high , Worsened , Recovered , and Consistently low ) using k-means longitudinal clustering. The primary outcome was ICU mortality; secondary outcomes were 6-month mortality and poor functional outcome (modified Rankin Scale 4–6). Associations of time-specific pupillometry indices and their longitudinal trajectories with outcomes were investigated. Results: Among 168 patients [age 69.6 ± 15.2 years; arrival GCS 7 (5–9); onset-to-arrival time 1.6 (0.9–5.2) h], ICU mortality was 29.8%. The Worsened and Consistently low NPi trajectory groups exhibited higher ICU mortality compared to the Consistently high group, while the Recovered group showed no significant difference. Incorporating NPi trajectories improved predictive accuracy for ICU mortality (AUROC, 0.89 vs. 0.80, p < 0.01), 6-month mortality (0.83 vs. 0.76, p = 0.01), and poor functional outcomes (0.87 vs. 0.82, p = 0.06) compared to a model using clinical variables alone. Conclusion: Ultra-early changes in pupillometry indices during the hyperacute phase enhance risk stratification and improve outcome prediction in acute brain injury.
- 12 June 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1741572
Open AccessUltra-early neurological pupil index trajectories and clinical outcomes in acute brain injury
Background and purpose: To investigate the association between ultra-early quantitative pupillometry indices measured within the first 24 h of emergency department (ED) arrival and clinical outcomes in patients with acute brain injury. Methods: This retrospective analysis of a prospectively collected database assessed patients admitted to the ICU of a tertiary hospital for acute brain injury (aneurysmal subarachnoid hemorrhage, traumatic brain injury, intracerebral hemorrhage, and ischemic stroke) between September 2022 and July 2024. Automated pupillometry was performed at 0, 1, 3, 6, and 24 h after ED arrival. Neurological pupil index (NPi) trajectories were categorized into four clusters ( Consistently high , Worsened , Recovered , and Consistently low ) using k-means longitudinal clustering. The primary outcome was ICU mortality; secondary outcomes were 6-month mortality and poor functional outcome (modified Rankin Scale 4–6). Associations of time-specific pupillometry indices and their longitudinal trajectories with outcomes were investigated. Results: Among 168 patients [age 69.6 ± 15.2 years; arrival GCS 7 (5–9); onset-to-arrival time 1.6 (0.9–5.2) h], ICU mortality was 29.8%. The Worsened and Consistently low NPi trajectory groups exhibited higher ICU mortality compared to the Consistently high group, while the Recovered group showed no significant difference. Incorporating NPi trajectories improved predictive accuracy for ICU mortality (AUROC, 0.89 vs. 0.80, p < 0.01), 6-month mortality (0.83 vs. 0.76, p = 0.01), and poor functional outcomes (0.87 vs. 0.82, p = 0.06) compared to a model using clinical variables alone. Conclusion: Ultra-early changes in pupillometry indices during the hyperacute phase enhance risk stratification and improve outcome prediction in acute brain injury.
- Open Access
- 30 April 2026
- Published by Korean Neurointensive Care Society in Journal of Neurointensive Care
- Vol. 9 (1) , 1-10
Evolution of the Monro-Kellie Doctrine from Static Intracranial Pressure to Dynamic Intracranial Physiology: A Critical Review of the Monro-Kellie 1.0 Through 4.0 Framework and Its Implications for Contemporary Neurocritical Care
The Monro-Kellie doctrine, first articulated in 1783, established that intracranial volume remains constant within the rigid cranium. However, this static three-compartment model has proven inadequate to explain the full complexity of intracranial pathophysiology. Sequential paradigm shifts—designated Monro-Kellie (MK) 1.0 through 4.0—have progressively transformed this foundational framework. MK 2.0 (Wilson, 2016) demonstrated that cerebral venous outflow dynamics, rather than static volume compensation, are the dominant determinant of acute intracranial pressure (ICP) fluctuations, with arterial inflow of approximately 700 mL/min dwarfing CSF production of 0.35 mL/min. MK 3.0 (Mangalore et al., 2019; Benson et al., 2022) revealed that brain tissue viscoelastic remodeling and calvarial structural adaptation constitute previously unrecognized compensatory mechanisms in chronic pressure dysregulation. MK 4.0 (Brasil et al., 2025) integrates cerebrovascular autoregulation assessment, glymphatic system physiology, and the novel concept of Intracranial Compartment Syndrome into a multimodal dynamic framework that challenges threshold-based ICP management. The Brussels International Consensus (B-ICONIC, 2025) has provided 34 evidence-based recommendations for noninvasive ICP monitoring implementation. This evolution necessitates a transition from threshold-driven management to individualized, physiology-guided neurocritical care incorporating continuous assessment of intracranial compliance, cerebrovascular reactivity, and glymphatic function.
- 30 April 2026
- Published by Korean Neurointensive Care Society in Journal of Neurointensive Care
- Vol. 9 (1) , 1-10
Open AccessEvolution of the Monro-Kellie Doctrine from Static Intracranial Pressure to Dynamic Intracranial Physiology: A Critical Review of the Monro-Kellie 1.0 Through 4.0 Framework and Its Implications for Contemporary Neurocritical Care
The Monro-Kellie doctrine, first articulated in 1783, established that intracranial volume remains constant within the rigid cranium. However, this static three-compartment model has proven inadequate to explain the full complexity of intracranial pathophysiology. Sequential paradigm shifts—designated Monro-Kellie (MK) 1.0 through 4.0—have progressively transformed this foundational framework. MK 2.0 (Wilson, 2016) demonstrated that cerebral venous outflow dynamics, rather than static volume compensation, are the dominant determinant of acute intracranial pressure (ICP) fluctuations, with arterial inflow of approximately 700 mL/min dwarfing CSF production of 0.35 mL/min. MK 3.0 (Mangalore et al., 2019; Benson et al., 2022) revealed that brain tissue viscoelastic remodeling and calvarial structural adaptation constitute previously unrecognized compensatory mechanisms in chronic pressure dysregulation. MK 4.0 (Brasil et al., 2025) integrates cerebrovascular autoregulation assessment, glymphatic system physiology, and the novel concept of Intracranial Compartment Syndrome into a multimodal dynamic framework that challenges threshold-based ICP management. The Brussels International Consensus (B-ICONIC, 2025) has provided 34 evidence-based recommendations for noninvasive ICP monitoring implementation. This evolution necessitates a transition from threshold-driven management to individualized, physiology-guided neurocritical care incorporating continuous assessment of intracranial compliance, cerebrovascular reactivity, and glymphatic function.
- Open Access
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5)
Temporal Patterns of Antithrombotic Therapy and Clinical Outcomes After Atrial Fibrillation‐Related Stroke
Background: This study aimed to describe the temporal evolution of antithrombotic treatment strategies and associated clinical outcomes after atrial fibrillation‐related acute ischemic stroke. Methods: This multicenter prospective cohort study enrolled patients with acute ischemic stroke and atrial fibrillation from 16 tertiary stroke centers across South Korea between February 2018 and January 2021, with follow‐up completed by January 2022. The primary outcome was a composite of recurrent stroke, myocardial infarction, and all‐cause death. Secondary outcomes included individual components of the primary outcome and major bleeding events. Results: The median follow‐up duration was 1.92 years. Among 2965 patients (mean±SD age, 75.3 [10.2] years; 54.1% male), antithrombotic strategies varied widely in the acute phase. Within 48 hours of admission, 50.9% received antiplatelet‐only therapy (29.4% single, 21.5% dual), 23.2% received non–vitamin K antagonist oral anticoagulant monotherapy, and 10.4% received a combination of antiplatelets and anticoagulants. By discharge, non–vitamin K antagonist oral anticoagulant monotherapy had become the predominant treatment strategy (65.7%), and this pattern persisted throughout follow‐up. The incidence of the primary end point was highest in the first 2 weeks (32.70 [95% CI, 29.64–36.06] per 100 person‐months) and declined thereafter. Across all time periods, patients receiving non–vitamin K antagonist oral anticoagulant monotherapy consistently had lower incidence rates (3‐month rate, 4.95 [95% CI, 4.37–5.61] per 100 person‐months) than those receiving antiplatelet‐only therapy (11.98 [95% CI, 9.57–15.01]) or no antithrombotic therapy (18.44 [95% CI, 14.26–23.86]). Conclusions: In this prospective cohort of patients with atrial fibrillation‐related stroke, early antithrombotic treatment strategies were heterogeneous but evolved primarily toward use of non–vitamin K antagonist oral anticoagulant monotherapy. Treatment selection was associated with marked differences in outcomes, particularly during the early high‐risk period.
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5)
Open AccessTemporal Patterns of Antithrombotic Therapy and Clinical Outcomes After Atrial Fibrillation‐Related Stroke
Background: This study aimed to describe the temporal evolution of antithrombotic treatment strategies and associated clinical outcomes after atrial fibrillation‐related acute ischemic stroke. Methods: This multicenter prospective cohort study enrolled patients with acute ischemic stroke and atrial fibrillation from 16 tertiary stroke centers across South Korea between February 2018 and January 2021, with follow‐up completed by January 2022. The primary outcome was a composite of recurrent stroke, myocardial infarction, and all‐cause death. Secondary outcomes included individual components of the primary outcome and major bleeding events. Results: The median follow‐up duration was 1.92 years. Among 2965 patients (mean±SD age, 75.3 [10.2] years; 54.1% male), antithrombotic strategies varied widely in the acute phase. Within 48 hours of admission, 50.9% received antiplatelet‐only therapy (29.4% single, 21.5% dual), 23.2% received non–vitamin K antagonist oral anticoagulant monotherapy, and 10.4% received a combination of antiplatelets and anticoagulants. By discharge, non–vitamin K antagonist oral anticoagulant monotherapy had become the predominant treatment strategy (65.7%), and this pattern persisted throughout follow‐up. The incidence of the primary end point was highest in the first 2 weeks (32.70 [95% CI, 29.64–36.06] per 100 person‐months) and declined thereafter. Across all time periods, patients receiving non–vitamin K antagonist oral anticoagulant monotherapy consistently had lower incidence rates (3‐month rate, 4.95 [95% CI, 4.37–5.61] per 100 person‐months) than those receiving antiplatelet‐only therapy (11.98 [95% CI, 9.57–15.01]) or no antithrombotic therapy (18.44 [95% CI, 14.26–23.86]). Conclusions: In this prospective cohort of patients with atrial fibrillation‐related stroke, early antithrombotic treatment strategies were heterogeneous but evolved primarily toward use of non–vitamin K antagonist oral anticoagulant monotherapy. Treatment selection was associated with marked differences in outcomes, particularly during the early high‐risk period.
- 22 January 2026
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (7) , 1030-1039
Sex differences in mortality and functional outcomes across stroke subtype: A nationwide cohort study
Background: Sex disparities in stroke outcomes are well-recognized, but it remains unclear whether these disparities vary across stroke subtypes and how they relate to differences in acute care delivery. Aim: The aim of the study was to examine sex differences in long-term mortality, functional outcomes, and acute stroke management across stroke subtypes using a nationwide population-based cohort. Methods: This retrospective cohort study analyzed linked clinical audit and claims data from 58,429 patients with acute stroke admitted to 269 hospitals in South Korea between 2018 and 2021. Clinical data were derived from the national Acute Stroke Quality Assessment Program and linked to claims. The primary outcome was all-cause mortality. The secondary outcome was poor functional outcome at discharge. Multivariable Cox and logistic regression models were used to assess associations between sex and outcomes, stratified by stroke subtype and adjusted for age, stroke severity, and comorbidities. Differences in acute stroke care were also analyzed. Results: Of 58,429 patients (mean [SD] age, 68.6 [13.8] years; 43.9% female), 76.1% had ischemic stroke (IS), 15.7% intracerebral hemorrhage (ICH), and 8.2% subarachnoid hemorrhage (SAH). Females were older than males across all subtypes and had different comorbidity profiles. After adjustment, females had significantly lower mortality in all subtypes (adjusted hazard ratios [95% CI]: IS, 0.77 [0.74–0.80]; ICH, 0.60 [0.56–0.64]; SAH, 0.60 [0.54–0.67]; all P < 0.001). Functional outcomes varied: females had worse outcomes in IS, better in ICH, and no difference in SAH. Males were more likely to receive reperfusion and surgical therapies; females were more likely to receive rehabilitation services. These care differences did not fully explain the observed disparities in outcomes. Conclusion: In this national cohort, sex disparities in stroke outcomes differed by subtype. Despite lower adjusted mortality in females, functional outcomes were not uniformly better. These findings underscore the importance of adopting sex- and subtype-specific approaches to stroke care, secondary prevention, and rehabilitation.
- 22 January 2026
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (7) , 1030-1039
Sex differences in mortality and functional outcomes across stroke subtype: A nationwide cohort study
Background: Sex disparities in stroke outcomes are well-recognized, but it remains unclear whether these disparities vary across stroke subtypes and how they relate to differences in acute care delivery. Aim: The aim of the study was to examine sex differences in long-term mortality, functional outcomes, and acute stroke management across stroke subtypes using a nationwide population-based cohort. Methods: This retrospective cohort study analyzed linked clinical audit and claims data from 58,429 patients with acute stroke admitted to 269 hospitals in South Korea between 2018 and 2021. Clinical data were derived from the national Acute Stroke Quality Assessment Program and linked to claims. The primary outcome was all-cause mortality. The secondary outcome was poor functional outcome at discharge. Multivariable Cox and logistic regression models were used to assess associations between sex and outcomes, stratified by stroke subtype and adjusted for age, stroke severity, and comorbidities. Differences in acute stroke care were also analyzed. Results: Of 58,429 patients (mean [SD] age, 68.6 [13.8] years; 43.9% female), 76.1% had ischemic stroke (IS), 15.7% intracerebral hemorrhage (ICH), and 8.2% subarachnoid hemorrhage (SAH). Females were older than males across all subtypes and had different comorbidity profiles. After adjustment, females had significantly lower mortality in all subtypes (adjusted hazard ratios [95% CI]: IS, 0.77 [0.74–0.80]; ICH, 0.60 [0.56–0.64]; SAH, 0.60 [0.54–0.67]; all P < 0.001). Functional outcomes varied: females had worse outcomes in IS, better in ICH, and no difference in SAH. Males were more likely to receive reperfusion and surgical therapies; females were more likely to receive rehabilitation services. These care differences did not fully explain the observed disparities in outcomes. Conclusion: In this national cohort, sex disparities in stroke outcomes differed by subtype. Despite lower adjusted mortality in females, functional outcomes were not uniformly better. These findings underscore the importance of adopting sex- and subtype-specific approaches to stroke care, secondary prevention, and rehabilitation.
- Open Access
Clinical Relevance of Concomitant Large Artery Steno-occlusion and Risk of Recurrent Stroke in Atrial Fibrillation
Background: Recurrent ischemic stroke remains a major concern in patients with nonvalvular atrial fibrillation (NVAF) despite anticoagulation. However, not all NVAF-related strokes are purely cardioembolic?concomitant large artery steno-occlusion (cLASO) is frequently observed and may represent an independent contributor to stroke recurrence. Current guidelines address these cases but focusing almost exclusively on the cardioembolic source. This approach contrasts sharply with the management of acute coronary syndrome in patients with NVAF, where identifying and targeting the 'culprit lesion' is standard practice. We evaluated whether the presence and clinical relevance of cLASO predict stroke recurrence in NVAF-related acute ischemic stroke (AIS). Methods: This prospective multicenter cohort study enrolled 2,035 patients with NVAF-related AIS at 14 stroke centers in South Korea between October 2017 and April 2020. Patients underwent brain magnetic resonance imaging and angiography. cLASO, defined as any degree of stenosis or occlusion in major cerebral arteries, was categorized by anatomical severity (mild, moderate-to-severe, or occlusion) and clinical relevance. Clinically relevant cLASO was defined as a steno-occlusive lesion topographically concordant with the infarction, thereby sufficiently explaining the index stroke regardless of concurrent cardioembolic source; otherwise, lesions were classified as bystander. The primary outcome was recurrent ischemic stroke within 3 years, analyzed using competing risk analysis. Results: Among 2,035 patients (mean age, 74.9 years; 54.8% male), 1,308 (64.3%) had cLASO, and 583 (28.6%) had clinically relevant cLASO. The 3-year cumulative incidence of recurrent ischemic stroke was 7.0%, with over 40% of recurrences occurring within the first month. Recurrence risk increased significantly with cLASO presence (4.5% vs. 8.1%), severity (mild, 5.7%; moderate-to-severe, 9.7%; occlusion, 9.1%) and clinical relevance (bystander, 3.8%; relevant, 13.9%) (all P?s < 0.05). In multivariable analysis, clinical relevance?rather than severity?was independently associated with recurrence (aHR, 4.10; 95% CI, 2.57-6.54). Conclusions: Clinically relevant cLASO identifies a mechanistically distinct, high-risk phenotype that warrants a paradigm shift from a uniform cardioembolic model toward a 'lesion-specific approach. The early clustering of recurrence suggests an urgent window for intervention. This well-characterized phenotype may represent a potential target population for future trials evaluating intensified antithrombotic strategies that address both cardioembolic and atherothrombotic pathways.
Open AccessClinical Relevance of Concomitant Large Artery Steno-occlusion and Risk of Recurrent Stroke in Atrial Fibrillation
Background: Recurrent ischemic stroke remains a major concern in patients with nonvalvular atrial fibrillation (NVAF) despite anticoagulation. However, not all NVAF-related strokes are purely cardioembolic?concomitant large artery steno-occlusion (cLASO) is frequently observed and may represent an independent contributor to stroke recurrence. Current guidelines address these cases but focusing almost exclusively on the cardioembolic source. This approach contrasts sharply with the management of acute coronary syndrome in patients with NVAF, where identifying and targeting the 'culprit lesion' is standard practice. We evaluated whether the presence and clinical relevance of cLASO predict stroke recurrence in NVAF-related acute ischemic stroke (AIS). Methods: This prospective multicenter cohort study enrolled 2,035 patients with NVAF-related AIS at 14 stroke centers in South Korea between October 2017 and April 2020. Patients underwent brain magnetic resonance imaging and angiography. cLASO, defined as any degree of stenosis or occlusion in major cerebral arteries, was categorized by anatomical severity (mild, moderate-to-severe, or occlusion) and clinical relevance. Clinically relevant cLASO was defined as a steno-occlusive lesion topographically concordant with the infarction, thereby sufficiently explaining the index stroke regardless of concurrent cardioembolic source; otherwise, lesions were classified as bystander. The primary outcome was recurrent ischemic stroke within 3 years, analyzed using competing risk analysis. Results: Among 2,035 patients (mean age, 74.9 years; 54.8% male), 1,308 (64.3%) had cLASO, and 583 (28.6%) had clinically relevant cLASO. The 3-year cumulative incidence of recurrent ischemic stroke was 7.0%, with over 40% of recurrences occurring within the first month. Recurrence risk increased significantly with cLASO presence (4.5% vs. 8.1%), severity (mild, 5.7%; moderate-to-severe, 9.7%; occlusion, 9.1%) and clinical relevance (bystander, 3.8%; relevant, 13.9%) (all P?s < 0.05). In multivariable analysis, clinical relevance?rather than severity?was independently associated with recurrence (aHR, 4.10; 95% CI, 2.57-6.54). Conclusions: Clinically relevant cLASO identifies a mechanistically distinct, high-risk phenotype that warrants a paradigm shift from a uniform cardioembolic model toward a 'lesion-specific approach. The early clustering of recurrence suggests an urgent window for intervention. This well-characterized phenotype may represent a potential target population for future trials evaluating intensified antithrombotic strategies that address both cardioembolic and atherothrombotic pathways.
- Open Access
- 20 August 2025
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 46 (6) , 1506-1515
Targeted proteomic analysis identifies ACVRL1 as a marker of cerebral edema in aneurysmal subarachnoid hemorrhage
Cerebral edema (CE) is a major component of early brain injury from aneurysmal subarachnoid hemorrhage (SAH). Despite the utility of blood-based protein markers, biomarkers targeting cerebral edema have yet to be developed. We performed a targeted proteomic search analyzing 141 proteins in plasma samples taken from 80 adult patients within 48 hours after aneurysmal rupture to identify plasma biomarkers of cerebral edema. The protein expression profiles were analyzed for associations with a higher level of the subarachnoid hemorrhage early brain edema score measured in admission computed tomography scans. Five differentially expressed proteins—brorin, ectodysplasin A2 receptor, layilin, scavenger receptor class A member 5, and activin A receptor like type 1 (ACVRL1)—were identified. To confirm our findings, in a separate cohort of 75 adult patients with SAH, these biomarker candidates was analyzed using a different confirmatory analytic method—enzyme-linked immunosorbent assay—based on the plasma samples collected within 48 hours after aneurysmal rupture. ACVRL1 levels consistently showed a decrease expression levels as the severity of edema increased. The association between CE and ACVRL1 was significant before and after adjusting for patient factors.
- 20 August 2025
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 46 (6) , 1506-1515
Open AccessTargeted proteomic analysis identifies ACVRL1 as a marker of cerebral edema in aneurysmal subarachnoid hemorrhage
Cerebral edema (CE) is a major component of early brain injury from aneurysmal subarachnoid hemorrhage (SAH). Despite the utility of blood-based protein markers, biomarkers targeting cerebral edema have yet to be developed. We performed a targeted proteomic search analyzing 141 proteins in plasma samples taken from 80 adult patients within 48 hours after aneurysmal rupture to identify plasma biomarkers of cerebral edema. The protein expression profiles were analyzed for associations with a higher level of the subarachnoid hemorrhage early brain edema score measured in admission computed tomography scans. Five differentially expressed proteins—brorin, ectodysplasin A2 receptor, layilin, scavenger receptor class A member 5, and activin A receptor like type 1 (ACVRL1)—were identified. To confirm our findings, in a separate cohort of 75 adult patients with SAH, these biomarker candidates was analyzed using a different confirmatory analytic method—enzyme-linked immunosorbent assay—based on the plasma samples collected within 48 hours after aneurysmal rupture. ACVRL1 levels consistently showed a decrease expression levels as the severity of edema increased. The association between CE and ACVRL1 was significant before and after adjusting for patient factors.
- Open Access
Temporal Patterns of Antithrombotic Therapy and Clinical Outcomes After Atrial Fibrillation-Related Stroke
Background: There is clinical equipoise in relation to the optimal timing and strategy for antithrombotic therapy in acute ischemic stroke (AIS) patients with atrial fibrillation (AF) who may be eligible for non-vitamin K antagonist oral anticoagulants (NOACs). This study aimed to describe the temporal evolution of antithrombotic treatment strategies and associated clinical outcomes after AF-related AIS. Methods: This multicenter prospective cohort study enrolled 2,965 patients with AIS and AF from 16 tertiary stroke centers across South Korea between February 2018 and January 2021, with follow-up completed by January 2022. The primary outcome was a composite of recurrent stroke, myocardial infarction, and all-cause death. Secondary outcomes included individual components of the primary outcome and major bleeding events. Results: The median follow-up duration was 1.92 years. Among 2,965 patients (mean [SD] age, 75.3 [10.2] years; 54.1% male), antithrombotic strategies varied widely in the acute phase. Within 48 hours of admission, 50.9% received antiplatelet-only therapy (29.4% single, 21.5% dual), 23.2% received NOAC monotherapy, and 10.4% received a combination of antiplatelets and anticoagulants. By discharge, NOAC monotherapy had become the predominant treatment strategy (65.7%), and this pattern persisted throughout follow-up. This treatment heterogeneity coincided with distinct temporal patterns in clinical outcomes. The incidence of the primary endpoint was highest in the first two weeks (32.70 [95% CI, 29.64-36.06] per 100 person-months), and declined thereafter. Across all time periods, patients receiving NOAC monotherapy consistently had lower incidence rates (3-month rate: 4.95 [95% CI, 4.37-5.61] per 100 person-months) than those receiving antiplatelet-only therapy (11.98 [95% CI, 9.57-15.01]) or no antithrombotic therapy (18.44 [95% CI, 14.26-23.86]). Conclusions: In this prospective cohort of patients with AF-related stroke, early antithrombotic treatment strategies were heterogeneous but evolved primarily toward use of NOAC monotherapy by the time of discharge from the hospital and during longitudinal follow-up. Treatment selection was associated with marked differences in outcomes, particularly during the early high-risk period. These findings underscore the need for safe and effective, time-sensitive antithrombotic strategies, especially in patients for whom immediate anticoagulation is deferred. Clinical Perspective: What Is New?: This nationwide prospective cohort study evaluated temporal trends in antithrombotic therapy and outcomes in patients with atrial fibrillation (AF)-related ischemic stroke. There was substantial heterogeneity in early treatment strategies, which converged toward NOAC (non–vitamin K antagonist oral anticoagulant) monotherapy by discharge. The risk of recurrent vascular events and death was highest during the first 2 weeks post-stroke and varied significantly by antithrombotic regimen. What Are the Clinical Implications?: The early post-stroke period represents a critical window with elevated risk and variable treatment practices. NOAC monotherapy was consistently associated with the lowest event rates, supporting early initiation when feasible. Timely and individualized antithrombotic strategies are essential to improve outcomes, especially for patients in whom anticoagulation is initially deferred.
Open AccessTemporal Patterns of Antithrombotic Therapy and Clinical Outcomes After Atrial Fibrillation-Related Stroke
Background: There is clinical equipoise in relation to the optimal timing and strategy for antithrombotic therapy in acute ischemic stroke (AIS) patients with atrial fibrillation (AF) who may be eligible for non-vitamin K antagonist oral anticoagulants (NOACs). This study aimed to describe the temporal evolution of antithrombotic treatment strategies and associated clinical outcomes after AF-related AIS. Methods: This multicenter prospective cohort study enrolled 2,965 patients with AIS and AF from 16 tertiary stroke centers across South Korea between February 2018 and January 2021, with follow-up completed by January 2022. The primary outcome was a composite of recurrent stroke, myocardial infarction, and all-cause death. Secondary outcomes included individual components of the primary outcome and major bleeding events. Results: The median follow-up duration was 1.92 years. Among 2,965 patients (mean [SD] age, 75.3 [10.2] years; 54.1% male), antithrombotic strategies varied widely in the acute phase. Within 48 hours of admission, 50.9% received antiplatelet-only therapy (29.4% single, 21.5% dual), 23.2% received NOAC monotherapy, and 10.4% received a combination of antiplatelets and anticoagulants. By discharge, NOAC monotherapy had become the predominant treatment strategy (65.7%), and this pattern persisted throughout follow-up. This treatment heterogeneity coincided with distinct temporal patterns in clinical outcomes. The incidence of the primary endpoint was highest in the first two weeks (32.70 [95% CI, 29.64-36.06] per 100 person-months), and declined thereafter. Across all time periods, patients receiving NOAC monotherapy consistently had lower incidence rates (3-month rate: 4.95 [95% CI, 4.37-5.61] per 100 person-months) than those receiving antiplatelet-only therapy (11.98 [95% CI, 9.57-15.01]) or no antithrombotic therapy (18.44 [95% CI, 14.26-23.86]). Conclusions: In this prospective cohort of patients with AF-related stroke, early antithrombotic treatment strategies were heterogeneous but evolved primarily toward use of NOAC monotherapy by the time of discharge from the hospital and during longitudinal follow-up. Treatment selection was associated with marked differences in outcomes, particularly during the early high-risk period. These findings underscore the need for safe and effective, time-sensitive antithrombotic strategies, especially in patients for whom immediate anticoagulation is deferred. Clinical Perspective: What Is New?: This nationwide prospective cohort study evaluated temporal trends in antithrombotic therapy and outcomes in patients with atrial fibrillation (AF)-related ischemic stroke. There was substantial heterogeneity in early treatment strategies, which converged toward NOAC (non–vitamin K antagonist oral anticoagulant) monotherapy by discharge. The risk of recurrent vascular events and death was highest during the first 2 weeks post-stroke and varied significantly by antithrombotic regimen. What Are the Clinical Implications?: The early post-stroke period represents a critical window with elevated risk and variable treatment practices. NOAC monotherapy was consistently associated with the lowest event rates, supporting early initiation when feasible. Timely and individualized antithrombotic strategies are essential to improve outcomes, especially for patients in whom anticoagulation is initially deferred.
- Open Access
- 22 July 2025
- Published by Springer Nature in Neurocritical Care
- Vol. 43 (3) , 810-823
Epidemiological Patterns and Variability in Acute Brain Injury: A Multicenter Registry Analysis in South Korea’s Neurocritical Care Units
Background: Specialized neurocritical care (NCC) improves outcomes in acute brain injury (ABI), but significant variability exists in practices across and hospitals within South Korea’s developing national NCC system. This study aims to assess clinical variability among patients with ABI across six tertiary NCC units (NCCUs) in South Korea and evaluate center-specific effects on clinical outcomes. Methods: A multicenter registry of patients with ABI admitted to NCCUs between April 2023 and April 2024 was analyzed. A descriptive analysis was conducted to evaluate demographic, clinical, and treatment characteristics across centers. Variability across centers was quantified using the average standardized mean difference (SMD) for key variables. Mixed-effects and fixed-effects models compared center-specific effects on 6- and 12-month functional outcomes (utility-weighted modified Rankin scale [mRS] score), in-hospital mortality, length of NCCU stay, and tracheostomy rates. Results: Among 1,125 patients, 202 (18.2%) had aneurysmal subarachnoid hemorrhage, 478 (42.5%) had intracerebral hemorrhage, and 442 (39.3%) had traumatic brain injury. The median Glasgow Coma Scale (GCS) score was 13 (interquartile range 7–15). Notable differences (SMD > 0.2) were observed in premorbid mRS scores, initial clinical severity (e.g., GCS, pupillary response), treatment practices (e.g. intracranial pressure monitoring, vasospasm prophylaxis), and outcomes (e.g., 6-month mRS score). Hospital-specific effects did not significantly influence most outcomes; mixed-effects models showed no significant improvement in model fit for 6-month mRS scores ( P = 0.78), in-hospital mortality ( P = 0.99), length of NCCU stay ( P = 0.12), and tracheostomy rates ( P = 0.11), except for the 12-month mRS score ( P = 0.01). Conclusions: Significant variability exists among patients with ABI across NCCUs in South Korea. Despite these differences, center-specific effects did not significantly influence key clinical outcomes closely related to NCCU care, suggesting that variability in outcomes may be more attributable to patient-level factors.
- 22 July 2025
- Published by Springer Nature in Neurocritical Care
- Vol. 43 (3) , 810-823
Open AccessEpidemiological Patterns and Variability in Acute Brain Injury: A Multicenter Registry Analysis in South Korea’s Neurocritical Care Units
Background: Specialized neurocritical care (NCC) improves outcomes in acute brain injury (ABI), but significant variability exists in practices across and hospitals within South Korea’s developing national NCC system. This study aims to assess clinical variability among patients with ABI across six tertiary NCC units (NCCUs) in South Korea and evaluate center-specific effects on clinical outcomes. Methods: A multicenter registry of patients with ABI admitted to NCCUs between April 2023 and April 2024 was analyzed. A descriptive analysis was conducted to evaluate demographic, clinical, and treatment characteristics across centers. Variability across centers was quantified using the average standardized mean difference (SMD) for key variables. Mixed-effects and fixed-effects models compared center-specific effects on 6- and 12-month functional outcomes (utility-weighted modified Rankin scale [mRS] score), in-hospital mortality, length of NCCU stay, and tracheostomy rates. Results: Among 1,125 patients, 202 (18.2%) had aneurysmal subarachnoid hemorrhage, 478 (42.5%) had intracerebral hemorrhage, and 442 (39.3%) had traumatic brain injury. The median Glasgow Coma Scale (GCS) score was 13 (interquartile range 7–15). Notable differences (SMD > 0.2) were observed in premorbid mRS scores, initial clinical severity (e.g., GCS, pupillary response), treatment practices (e.g. intracranial pressure monitoring, vasospasm prophylaxis), and outcomes (e.g., 6-month mRS score). Hospital-specific effects did not significantly influence most outcomes; mixed-effects models showed no significant improvement in model fit for 6-month mRS scores ( P = 0.78), in-hospital mortality ( P = 0.99), length of NCCU stay ( P = 0.12), and tracheostomy rates ( P = 0.11), except for the 12-month mRS score ( P = 0.01). Conclusions: Significant variability exists among patients with ABI across NCCUs in South Korea. Despite these differences, center-specific effects did not significantly influence key clinical outcomes closely related to NCCU care, suggesting that variability in outcomes may be more attributable to patient-level factors.